Orchard Therapeutics (ORTX)
NASDAQ: ORTX
· Real-Time Price · USD
16.70
0.05 (0.30%)
At close: Jan 23, 2024, 10:00 PM
Orchard Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 6.3M | 7.31M | 1.24M | 6.99M | 5.78M | 4.37M | 5.52M | 483K | 1.19M | n/a | n/a |
Cost of Revenue | 1.75M | 2.19M | 367K | -1.91M | 1.65M | 1.12M | 1.57M | n/a | 226K | n/a | n/a |
Gross Profit | 4.56M | 5.13M | 870K | 8.89M | 4.13M | 3.25M | 3.95M | 483K | 966K | n/a | n/a |
Operating Income | -21.61M | -22.56M | -26.26M | 133.08M | -25.57M | -32.45M | -37.58M | -36.41M | -32.92M | -36.01M | -35.09M |
Interest Income | 1.5M | 1.39M | 1.03M | 857K | 404K | 213K | 69K | 63K | 65K | 113K | 171K |
Pretax Income | -34.34M | -12.28M | -17.42M | 135.01M | -48.65M | -51.13M | -44.24M | -36.22M | -37.58M | -35.86M | -34.09M |
Net Income | -35.32M | -12.31M | -17.41M | 134.89M | -47.56M | -50.92M | -44.3M | -36.35M | -36.45M | -36.61M | -35.18M |
Selling & General & Admin | 11.61M | 10.99M | 11.13M | -27.59M | 11.6M | 13.73M | 13.3M | 13.55M | 13.04M | 14.26M | 14.05M |
Research & Development | 14.55M | 16.7M | 15.99M | -42.76M | 18.1M | 21.96M | 28.23M | 23.35M | 20.85M | 21.75M | 21.04M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 26.16M | 27.69M | 27.13M | -70.35M | 29.71M | 35.7M | 41.53M | 36.9M | 33.88M | 36.01M | 35.09M |
Interest Expense | 932K | 975K | 957K | 933K | 799K | 672K | 675K | 683K | 683K | 593K | 538K |
Selling & Marketing Expenses | 775K | 933K | 838K | 895K | 927K | 1.54M | 773K | 1.59M | 1.52M | 1.05M | 1.1M |
Cost & Expenses | 27.91M | 29.88M | 27.5M | -72.25M | 31.35M | 36.82M | 43.1M | 36.9M | 34.11M | 36.01M | 35.09M |
Income Tax Expense | -976K | 25K | -12K | 116K | -1.08M | -219K | 58K | 124K | -1.13M | 750K | 1.09M |
Shares Outstanding (Basic) | 22.84M | 18.93M | 14.18M | 12.82M | 12.81M | 12.79M | 12.77M | 12.75M | 12.74M | 12.6M | 11.48M |
Shares Outstanding (Diluted) | 22.84M | 18.93M | 14.18M | 12.82M | 12.81M | 12.79M | 12.77M | 12.76M | 12.74M | 12.6M | 11.48M |
EPS (Basic) | -1.55 | -0.65 | -1.23 | 10.52 | -3.71 | -3.98 | -3.47 | -0.29 | -2.86 | -2.91 | -3.06 |
EPS (Diluted) | -1.55 | -0.65 | -1.23 | 10.52 | -3.71 | -3.98 | -3.47 | -0.29 | -2.86 | -2.91 | -3.06 |
EBITDA | -21.61M | -19.51M | -19.68M | 133.8M | -47.3M | -49.81M | -42.85M | -34.87M | -36.25M | -34.76M | -33.06M |
EBIT | -35.27M | -11.31M | -16.47M | -30.87M | -47.98M | -50.46M | -43.56M | -35.54M | -36.9M | -35.27M | -33.56M |
Depreciation & Amortization | 652K | 3.05M | 6.58M | 721K | -21.73M | -17.36M | -5.27M | 676K | 648K | 508K | 495K |